These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2185687)

  • 1. Circulating tumor markers in breast cancer (review).
    Jotti GS; Bombardieri E
    Anticancer Res; 1990; 10(1):253-8. PubMed ID: 2185687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum markers for breast cancer.
    Stenman UH; Heikkinen R
    Scand J Clin Lab Invest Suppl; 1991; 206():52-9. PubMed ID: 1947760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of tumour markers CA50, CEA and TPA in female breast carcinoma as related to histopathological findings and survival.
    Eskelinen M; Lipponen P; Syrjänen K
    Anticancer Res; 1992; 12(1):91-5. PubMed ID: 1567186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer].
    Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
    Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value and limitations of neoplasm markers in the diagnosis of pancreatic carcinoma].
    Fabris C; Basso D; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Ferrara C; Scalon P; Naccarato R
    Recenti Prog Med; 1991 Mar; 82(3):166-72. PubMed ID: 2047559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical evaluation of tumor markers in breast cancer patients].
    Ito T; Tanaka S; Ban K; Sakai N; Oshita H; Oiwa T; Kanno A; Kashizuka T
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2917-23. PubMed ID: 3310907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
    Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G
    Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tumor markers in the diagnosis and prognosis of breast cancer].
    Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
    Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
    Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
    J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
    Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
    Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing tumor markers in breast cancer: monitoring, prognosis, and therapy control.
    Staab HJ; Ahlemann LM; Anderer FA; Zwirner M; Schindler AE
    Cancer Detect Prev; 1985; 8(1-2):35-45. PubMed ID: 4064050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical evaluation of tumor markers in patients with colorectal cancer].
    Naritaka Y; Ogawa K; Matsumoto N; Hosokawa T; Kikuchi T; Koyama N; Haga S; Kajiwara T; Sakakibara N
    Gan No Rinsho; 1987 Aug; 33(10):1274-80. PubMed ID: 2444727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of various tumor markers in pleural effusion and in the serum].
    Jibiki K; Abe Y; Takeda M; Iwachika C; Odagiri E; Demura R; Demura H
    Gan No Rinsho; 1989 Aug; 35(9):991-8. PubMed ID: 2769951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The tumor markers CEA, TPA and CA 19-9 and ferritin and osteocalcin in follow-up studies in breast cancer].
    Schatz C; von Lieven H; Mulders M; Rowold J; Stracke H; Müller H; Grebe SF; Schatz H
    Wien Klin Wochenschr; 1985 Dec; 97(23):873-9. PubMed ID: 3878042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum marker combinations in human breast cancer (review).
    Lamerz R; Stieber P; Fateh-Moghadam A
    In Vivo; 1993; 7(6B):607-13. PubMed ID: 8193281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How can treatment response be measured in breast cancer patients?
    van Dalen A; van der Linde DL; Heering KJ; van Oudalblas AB
    Anticancer Res; 1993; 13(5C):1901-4. PubMed ID: 8267398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
    Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
    Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCA performance in preoperative breast cancer patients.
    Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
    Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.